Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENESIS study of motixafortide plus G-CSF for stem cell mobilization in multiple myeloma
2018-001715-79Phase 3Active
- Sponsor
- BioLineRx Ltd.
- Start
- Mar 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Motixafortide + G-CSF with Placebo + G-CSF (2 arms). Primary endpoint: Successful collection of at least 6.0 x 10^6 CD34+ cells/kg in up to 2 apheresis sessions. Started Mar 2019; status: active.
02
Drugs
motixafortidefilgrastim
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-001715-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001715-79.